An interventional study of blood sample in Cardiac Surgery and Acute Kidney Injury, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Other
Cardiac surgery and cardiopulmonary bypass can lead to systemic organ failure trough excess inflammation and endothelial injury. The angiopoietin family represented by angiopoietin 1 and 2 can reflect endothelial injury by a decrease in angiopoietin 1 and an increase in angiopoietin 2. The investigators hypothesized that angiopoietin dysregulation could reflect organ failure related to cardiac surgery.
The purpose of this project is to assess the association between angiopoietin dysregulation and adverse outcomes on cardiac surgery.
1,595 studies on the registry are indexed under Acute Kidney Injury; 371 are open to participants now.
This study's planned enrollment of 200 is above the median of 100 across 763 interventional studies indexed under Acute Kidney Injury.
Browse Acute Kidney Injury studies →Centre Hospitalier Universitaire, Amiens is the lead sponsor of 576 studies on the registry; 178 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: blood sample
5 ml blood sample will be withdrawn at the surgery start and at the surgery end
Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of major cardiovascular event
major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death
Time frame: 28 days
correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and occurence of major cardiovascular event
major cardiovascular event are myocardial infraction, stroke, acute kidney injury, cardiovascular death
Time frame: 28 days
Correlation between abnormal angiopoietin 1 concentration (ng/ml) and number of postoperative pulmonary complications
Time frame: 28 days
Correlation between abnormal angiopoietin 2 concentration (ng/ml) and number of postoperative pulmonary complications
Time frame: 28 days
Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 3 months
Time frame: 3 months
Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality at 3 months
Time frame: 3 months
Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality at 6 months
Time frame: 6 months
Correlation between occurence of abnormal angiopoietin 2 concentration (ng/ml) and mortality at 6 months
Time frame: 6 months
Correlation between abnormal angiopoietin 1 concentration (ng/ml) and mortality rate at 12 months
Time frame: 12 months
Correlation between abnormal angiopoietin 2 concentration (ng/ml) and mortality rate at 12 months
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire, Amiens